Michael R Winters

US Patent:

7767399, Aug 3, 2010

Filed:

Jan 27, 2006

Appl. No.:

11/795908

Inventors:

Jason C. Murphy - Ambler PA, US
David B. Boyd - Quakertown PA, US
Adam Joel Kristopeit - North Wales PA, US
Russel Jackson Lander - Lansdale PA, US
Michael Albert Winters - Doylestown PA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Methods of isolating clinical-grade plasmid DNA from manufacturing processes, including large-scale fermentation regimes, are disclosed which encompass alternatives to two core unit operations common to plasmid DNA purification processes. The novel upstream and downstream purification processes disclosed herein provide for reduced production costs and increase process robustness. Either or both of the purification processes disclosed herein may be used in combination with additional purification steps known in the art that are associated with DNA plasmid purification technology.

US Patent:

20230073288, Mar 9, 2023

Filed:

Feb 24, 2021

Appl. No.:

17/800271

Inventors:

Jennifer C. P. WANG - West Point PA, US
Kelsey A. RICHARDS - Philadelphia PA, US
Jayesh DESAI - Kenilworth NJ, US
Bhumit A. PATEL - Kenilworth NJ, US
Michael A. WINTERS - West Point PA, US
Patrick M. MCHUGH - West Point PA, US
Philip R. KUHL - West Point PA, US
John P. HIGGINS - West Point PA, US
Michael I. LARKIN - Santa Barbara CA, US
Michelle H. CHEN - Goleta CA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme LLC - Rahway NJ

International Classification:

A61K 39/09
C08B 37/00

Abstract:

The present invention relates to Polysaccharide Size-Reduction Monitoring Methods useful for the non-invasive, and accurate monitoring of the progress of a polysaccharide size-reduction process.

US Patent:

20210252125, Aug 19, 2021

Filed:

Apr 25, 2019

Appl. No.:

17/049245

Inventors:

Patrick Leonard AHL - West Point PA, US
Akhilesh BHAMBHANI - West Point PA, US
Christopher Jon FARRELL - West Point PA, US
Patrick MCHUGH - West Point PA, US
Morrisa C. JONES - West Point PA, US
Daniel D. ROTH - West Point PA, US
Jessica R. SINACOLA - West Point PA, US
Justin STANBRO - West Point PA, US
Matthew P. WATSON - West Point PA, US
Emily WEN - West Point PA, US
Michael A. WINTERS - West Point PA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/09
A61K 47/62
A61K 47/61

Abstract:

A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.

US Patent:

20210236646, Aug 5, 2021

Filed:

Apr 25, 2019

Appl. No.:

17/049208

Inventors:

Patrick Leonard AHL - West Point PA, US
Akhilesh BHAMBHANI - West Point PA, US
Patrick MHUGH - West Point PA, US
Morrisa C. JONES - West Point PA, US
Daniel D. ROTH - West Point PA, US
Jessica R. SINACOLA - West Point PA, US
Justin STANBRO - West Point PA, US
Matthew P. WATSON - West Point PA, US
Emily WEN - WestPoint PA, US
Michael A. WINTERS - West Point PA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 47/61
A61K 39/09

Abstract:

A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized in the form of lyospheres of carrier protein and lyospheres of the one or more polysaccharides. A predetermined amount of carrier protein lyospheres and activated polysaccharide lyospheres are mixed together and the mixture reconstituted in an organic solvent to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.

US Patent:

20200061179, Feb 27, 2020

Filed:

Feb 20, 2018

Appl. No.:

16/487621

Inventors:

John E. MACNAIR - West Point PA, US
Michael A. WINTERS - West Point PA, US
Thomas SVAB - West Point PA, US
Sheng-Ching WANG - West Point PA, US
William J. SMITH - West Point PA, US
Cecilia GIOVARELLI - West Point PA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/09
A61K 47/64
C07K 14/34

Abstract:

The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which polysaccharides obtained from bacterial capsules are conjugated to diphtheria toxin fragment B (DTFB) or a variant thereof. The immunogenic compositions may be multivalent pneumococcal polysaccharide conjugate compositions in which polysaccharides from one or more serotypes are conjugated to diphtheria toxin fragment B (DTFB) and, optionally, additional polysaccharides from one or more different serotypes are conjugated to one or more other carrier proteins.